Vetenskapliga publikationer
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
2024
Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease
https://pubmed.ncbi.nlm.nih.gov/38637457/
Construct validity of EQ-5D-5L among patients with inflammatory bowel disease-a study based on real-world data from the Swedish Inflammatory Bowel Disease Registry
https://pubmed.ncbi.nlm.nih.gov/38536626/
Histologic Remission in Inflammatory Bowel Disease and Female Fertility: A Nationwide Study
https://pubmed.ncbi.nlm.nih.gov/38331202/
Histologic Activity in Inflammatory Bowel Disease and Risk of Serious Infections: A Nationwide Study
https://pubmed.ncbi.nlm.nih.gov/37913937/
2023
Increasing healthcare costs in inflammatory bowel disease 2007-2020 in Sweden
https://pubmed.ncbi.nlm.nih.gov/37594381/
Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study
https://pubmed.ncbi.nlm.nih.gov/37274297/
Colectomy in patients with ulcerative colitis is not associated to future diagnosis of primary sclerosing cholangitis
https://pubmed.ncbi.nlm.nih.gov/37169725/
Increasing Risk of Lymphoma Over Time in Crohn’s Disease but Not in Ulcerative Colitis: A Scandinavian Cohort Study
https://pubmed.ncbi.nlm.nih.gov/37061104/
Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn’s Disease
https://pubmed.ncbi.nlm.nih.gov/36929241/
The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study
https://pubmed.ncbi.nlm.nih.gov/35776552/
Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn’s Disease
https://pubmed.ncbi.nlm.nih.gov/35459973/
2022
Histological remission in inflammatory bowel disease and risk of adverse pregnancy outcomes: A nationwide study.
https://pubmed.ncbi.nlm.nih.gov/36467453/
Ustekinumab treatment in ulcerative colitis: Real-world data from the Swedish inflammatory bowel disease quality register.
https://pubmed.ncbi.nlm.nih.gov/35834389/
The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study.
https://pubmed.ncbi.nlm.nih.gov/35776552/
Identification of Childhood-Onset Inflammatory Bowel Disease in Swedish Healthcare Registers: A Validation Study.
https://pubmed.ncbi.nlm.nih.gov/35520278/
Association Between Inflammatory Bowel Disease and Spondyloarthritis: Findings from a Nationwide Study in Sweden.
https://pubmed.ncbi.nlm.nih.gov/35512691/
Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn’s Disease.
https://pubmed.ncbi.nlm.nih.gov/35459973/
Prevalence and Implications of Frailty in Older Adults With Incident Inflammatory Bowel Diseases: A Nationwide Cohort Study.
https://pubmed.ncbi.nlm.nih.gov/34999206/
Tumour necrosis factor inhibitors in Crohn’s disease and the effect on surgery rates.
https://pubmed.ncbi.nlm.nih.gov/34905282/
Increased incidence of late-onset inflammatory bowel disease and microscopic colitis after a Cryptosporidium hominisoutbreak.
https://pubmed.ncbi.nlm.nih.gov/35802626/
2021
Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.
https://pubmed.ncbi.nlm.nih.gov/33340426/
Capturing biologic treatment for IBD in the Swedish Prescribed Drug Register and the Swedish National Patient Register – a validation study.
https://pubmed.ncbi.nlm.nih.gov/33632044/
2020
A Novel Method for Quantifying Intestinal Inflammatory Burden in Inflammatory Bowel Disease Using Register Data.
https://pubmed.ncbi.nlm.nih.gov/33116900/
Healthcare use, work loss and total costs in incident and prevalent Crohn’s disease and ulcerative colitis: results from a nationwide study in Sweden.
https://pubmed.ncbi.nlm.nih.gov/32902894/
The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register.
https://pubmed.ncbi.nlm.nih.gov/32370571/
Work Loss in Relation to Pharmacological and Surgical Treatment for Crohn’s Disease: A Population-Based Cohort Study.
https://pubmed.ncbi.nlm.nih.gov/32210631/
2019
Swedish Inflammatory Bowel Disease Register (SWIBREG) – a nationwide quality register.
https://www.ncbi.nlm.nih.gov/pubmed/31498717
Work Loss Before and After Diagnosis of Crohn’s Disease.
https://www.ncbi.nlm.nih.gov/pubmed/30551185
Validating surgical procedure codes for inflammatory bowel disease in the Swedish National PatientRegister.
https://www.ncbi.nlm.nih.gov/pubmed/31711471
2018
Clinical effectiveness of golimumab in Crohn’s disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
https://www.ncbi.nlm.nih.gov/pubmed/30353751
Sick leave and disability pension in prevalent patients with Crohn’s disease.
https://www.ncbi.nlm.nih.gov/pubmed/30165593
Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden.
https://www.ncbi.nlm.nih.gov/pubmed/29102619
2017
Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG).
https://www.ncbi.nlm.nih.gov/pubmed/27797278
Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)
https://www.ncbi.nlm.nih.gov/pubmed/28362144